Home Biosimilar Antibodies Immunology & Inflammation CD markers -LAG-3 Fianlimab (Anti-LAG3 / CD223)
For research use only. Not for use in humans.

Fianlimab (Anti-LAG3 / CD223)

Synonyms: LAG-3， CD223

Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.

Fianlimab (Anti-LAG3 / CD223)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
References

Product Details

CAS No. 2126132-98-5
Molecular Weight 145.72
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07365839 NOT_YET_RECRUITING Drug: Arm 1 cemiplimab|Drug: Arm 2 cemiplimab and fianlimab Hepatocellular Carcinoma Virginia Commonwealth University 2026-10-01 PHASE1
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT07346196 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Fianlimab|Drug: Carboplatin|Drug: Pac Squamous Cell Carcinoma University of Chicago 2027-02-07 PHASE2
NCT05929664 SUSPENDED Locally Advanced Basal Cell Carcinoma; Basal Cell Carcinoma Thomas Jefferson University 2023-07-05 PHASE2
NCT07650266 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Fianlimab Nasopharyngeal Carcinoma; Nasopharyngeal Cancer; Nasopharynx Carcinoma; Nasopharynx Cancer Memorial Sloan Kettering Cancer Center 2026-09 PHASE1
NCT07281768 RECRUITING Drug: Oxaliplatin|Drug: Capecitabine|Drug: Cemiplimab|Drug: Colorectal Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2026-07-14 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.